Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
02 2021
Historique:
received: 29 07 2020
revised: 19 10 2020
accepted: 25 12 2020
pubmed: 16 1 2021
medline: 22 6 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

Cognitive deficits are a central feature of schizophrenia whose etiology is not fully understood. Epstein Barr Virus (EBV) is a potentially neurotropic infectious agent that can generate persistent infections with immunomodulatory effects. Previous studies have found an association between EBV antibodies and cognitive functioning in different populations, but there has been limited investigation in schizophrenia. In this study, 84 individuals with schizophrenia were administered a comprehensive neuropsychological battery, the MATRICS Consensus Cognitive Battery (MCCB). Participants also provided a blood sample, from which antibodies to the EBV whole virion and specific proteins were measured. Multivariate models were constructed to determine the association between these antibodies and cognitive performance on the MCCB overall and domain scores. Using these models, we found a significant association between the MCCB overall percent composite score and level of antibodies to the EBV Nuclear Antigen-1 (EBNA-1) protein, the Viral Capsid Antigen (VCA) protein, and the EBV whole virion. A significant association was also found for the MCCB social cognition domain with the level of antibodies to the EBV Nuclear Antigen-1 (EBNA-1) protein, the Viral Capsid Antigen (VCA) protein, and the EBV whole virion. In all cases, a higher level of antibodies was associated with a lower level cognitive performance. These findings suggest that exposure to EBV may contribute to cognitive deficits in schizophrenia, a finding which may have implications for new methods of prevention and treatment.

Identifiants

pubmed: 33450604
pii: S0920-9964(21)00002-5
doi: 10.1016/j.schres.2020.12.018
pmc: PMC8023564
mid: NIHMS1685898
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Antigens, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

193-197

Subventions

Organisme : NIMH NIH HHS
ID : K23 MH118435
Pays : United States
Organisme : NIMH NIH HHS
ID : R34 MH100296
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Yolken is a member of the Stanley Medical Research Institute Board of Directors and Scientific Advisory Board. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. The other authors declare that there are no conflicts of interest in relation to the subject of this study.

Références

Neuropsychology. 1998 Jul;12(3):426-45
pubmed: 9673998
Schizophr Res. 2019 Apr;206:291-299
pubmed: 30478008
Sci Rep. 2017 Sep 19;7(1):11821
pubmed: 28928440
Schizophr Res. 2020 Aug;222:145-152
pubmed: 32591238
Curr Top Microbiol Immunol. 2015;391:289-323
pubmed: 26428379
Schizophr Res. 2012 Jan;134(1):76-82
pubmed: 22093182
PLoS One. 2014 Jul 01;9(7):e101549
pubmed: 24983885
J Med Virol. 1994 Jul;43(3):238-44
pubmed: 7931184
Pathogens. 2020 Jan 19;9(1):
pubmed: 31963774
Rev Clin Exp Hematol. 2003 Dec;7(4):362-74
pubmed: 15129648
Am J Psychiatry. 2008 Feb;165(2):214-20
pubmed: 18172018
Am J Psychiatry. 1994 Jan;151(1):40-8
pubmed: 8267133
J Affect Disord. 2020 Mar 1;264:221-226
pubmed: 32056754
Am J Psychiatry. 1996 Mar;153(3):321-30
pubmed: 8610818
Neurology. 2012 Jan 3;78(1):15-23
pubmed: 22156987
Trends Mol Med. 2020 Mar;26(3):296-310
pubmed: 31862243
Schizophr Bull. 2019 Sep 11;45(5):1112-1119
pubmed: 30462333
BMC Infect Dis. 2011 Oct 21;11:281
pubmed: 22018204
Brain Behav Immun. 2019 Feb;76:159-164
pubmed: 30465879
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Alzheimers Dis. 2015;47(2):351-64
pubmed: 26401558
Arch Gen Psychiatry. 2003 May;60(5):466-72
pubmed: 12742867
N Engl J Med. 1976 Jun 17;294(25):1355-9
pubmed: 177872
Mult Scler. 2010 Jul;16(7):883-7
pubmed: 20483883
Dev Psychopathol. 2018 Feb;30(1):143-152
pubmed: 28420448
PLoS One. 2014 May 20;9(5):e95510
pubmed: 24846058
Brain Behav Immun. 2018 Mar;69:480-485
pubmed: 29355820
Nat Rev Neurosci. 2015 Oct;16(10):620-31
pubmed: 26373471
J Infect Dis. 2005 Nov 1;192(9):1503-4
pubmed: 16206063
Schizophr Res. 1996 Aug 23;21(2):75-83
pubmed: 8873775

Auteurs

Faith Dickerson (F)

Sheppard Pratt Health System, Baltimore, MD, USA. Electronic address: fdickerson@sheppardpratt.org.

Emily Katsafanas (E)

Sheppard Pratt Health System, Baltimore, MD, USA.

Andrea Origoni (A)

Sheppard Pratt Health System, Baltimore, MD, USA.

Amalia Squire (A)

Sheppard Pratt Health System, Baltimore, MD, USA.

Sunil Khushalani (S)

Sheppard Pratt Health System, Baltimore, MD, USA.

Theresa Newman (T)

Sheppard Pratt Health System, Baltimore, MD, USA.

Kelly Rowe (K)

Sheppard Pratt Health System, Baltimore, MD, USA.

Cassie Stallings (C)

Sheppard Pratt Health System, Baltimore, MD, USA.

Christina L G Savage (CLG)

Sheppard Pratt Health System, Baltimore, MD, USA.

Kevin Sweeney (K)

Sheppard Pratt Health System, Baltimore, MD, USA.

Tanya T Nguyen (TT)

University of California San Diego, CA, USA; VA San Diego Healthcare System, CA, USA.

Alan Breier (A)

University of Indiana, Indianapolis, IN, USA.

Donald Goff (D)

New York University, New York, NY, USA.

Glen Ford (G)

VanPelt Biosciences, Rockville, MD, USA.

Lorraine Jones-Brando (L)

Johns Hopkins School of Medicine, Baltimore, MD, USA.

Robert Yolken (R)

Johns Hopkins School of Medicine, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH